Clinical Trials at Levine Cancer Institute
As of June 2026, 63 paid clinical trials are recruiting at Levine Cancer Institute, located at Atrium Health Levine Cancer Institute, 1021 Morehead Medical Dr, Charlotte, NC 28204, phone (980) 442-2000 in Charlotte, North Carolina. Active studies at this site cover conditions such as Multiple Myeloma, Acute Myeloid Leukemia and Breast Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
63 clinical trials at Levine Cancer Institute
·Clear filters·↓ Download CSVA Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Resilience Enhancement Using Electronic Frailty Index-Directed Care Pathway
Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Digoxin Medulloblastoma Study
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Patient Descriptors Of Cancer-Related Fatigue: A Mixed Methods Pilot Study Of Cancer Survivors
Discharge Medication Use Post-Operatively in GU Cancer Patients
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Study of SGR-3515 In Participants With Advanced Solid Tumors.
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
About research studies in Charlotte
Charlotte has approximately 556 recruiting research studies across a wide range of therapeutic areas. North Carolina hosts Duke University Medical Center, UNC Health, and Wake Forest Baptist Health, with strong programs in oncology, cardiovascular disease, and translational research anchored by Research Triangle Park.
Common conditions studied in Charlotte
- Multiple Myeloma (16 active studies). Recruiting Multiple Myeloma studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Acute Myeloid Leukemia (11 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Breast Cancer (9 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Heart Failure (8 active studies). Heart failure trials explore SGLT-2 inhibitors, novel myosin modulators, and device-based therapies for both reduced and preserved ejection fraction.
- Cancer (7 active studies). Recruiting Cancer studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Neuroblastoma (7 active studies). Recruiting Neuroblastoma studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in Charlotte
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
- AstraZeneca
- Janssen Research & Development, LLC
- AbbVie
Local regulations and guidelines
Clinical trials in North Carolina are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. North Carolina research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Charlotte. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Charlotte
Hipa.ai aggregates every recruiting study in Charlotte from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Charlotte?
There are approximately 556 recruiting clinical trials in Charlotte, North Carolina listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Charlotte pay participants?
Most recruiting trials in Charlotte compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Charlotte?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Charlotte?
The most common conditions under active study in Charlotte include Multiple Myeloma (16), Acute Myeloid Leukemia (11), Breast Cancer (9), Heart Failure (8), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Charlotte?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Charlotte on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Charlotte?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Charlotte?
Recruiting research sites in Charlotte include Levine Cancer Institute, Carolinas Medical Center/Levine Cancer Institute, Atrium Health, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Charlotte right now?
The largest active categories in Charlotte are Cancer & tumors (194), Neurology & pain (33), Cardiovascular (26). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Levine Cancer Institute?
Levine Cancer Institute is located at Atrium Health Levine Cancer Institute, 1021 Morehead Medical Dr, Charlotte, NC 28204. Use the Google Maps link in the intro above to get directions.
How do I contact Levine Cancer Institute?
You can reach Levine Cancer Institute by phone at (980) 442-2000. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.